Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Suspended 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Recurrence 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, T-Cell 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Leukemia-Lymphoma, Adult T-Cell 1Immunoblastic Lymphadenopathy 1Epstein-Barr Virus Infections 1

Interventions

Peripheral Blood Stem Cell Transplantation 5Cyclophosphamide 5romidepsin 4pembrolizumab 4Lenalidomide 4Etoposide 410-propargyl-10-deazaaminopterin 4Rituximab 3fludarabine phosphate 2fludarabine 2durvalumab 2carmustine, poliferprosan 20 drug combination 2Vincristine 2Prednisone 2N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 2Melphalan 2Gemcitabine 2Doxorubicin 2Depsipeptides 2Cytarabine 2Carmustine 2Bendamustine Hydrochloride 2AFM13 2veliparib 1thymoglobulin 1tenalisib 1temsirolimus 1prednylidene 1mogamulizumab 1forodesine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Lymphoma, T-Cell × brincidofovir × Clear all
NCT06761677 2026-02-05

A Phase 1b/2 Study of Intravenous Brincidofovir in Patients With Relapsed or Refractory Lymphoma and Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma

SymBio Pharmaceuticals

Phase 1/2 Suspended
43 enrolled
LymphoidOther hematologic neoplasm

Immunoblastic Lymphadenopathy, Lymphoma, Recurrence, Leukemia-Lymphoma, Adult T-Cell, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Large-Cell, Anaplastic, Epstein-Barr Virus Infections, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡